Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 21, 2008

Alnylam Grants Calando License to Further siRNA Cancer Therapeutic Program

  • Alnylam Pharmaceuticals granted Calando Pharmaceuticals an InterfeRx™ license to discover, develop, and commercialize a synthetic siRNA directed toward a specific cancer gene target.

    Under this nonexclusive agreement, Alnylam gains the right of first negotiation to opt-in for codevelopment and cocommercialization in the U.S. market. Financial terms include upfront and milestone payments as well as royalties.

    “Calando has demonstrated exciting progress with the only clinical-stage RNAi therapeutic oncology program currently in Phase I trials,” points out Jason Rhodes, vp, business development of Alnylam. “We are encouraged by the potential for similar success with this new target.”

    Alnylam created the InterfeRx program to grant licenses under its intellectual property to companies wishing to pursue RNAi therapeutics against specific targets outside its core strategic interests. In 2006, Alnylam granted Calando an InterfeRx license to develop and commercialize an RNAi therapeutic targeting the M2 subunit of ribonucleotide reductase (RRM2) formulated with Calando’s Rondel™ (RNAi/oligonucleotide nanoparticle delivery) polymer delivery system.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »